IBD: Medical Management

  • Bruce E. Sands


Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory conditions characterized by periods of symptomatic relapse and remission. The cause of inflammatory bowel disease (IBD) is unknown but it is believed to be caused by a combination of environmental, genetic, and immunological factors in which an uncontrolled immune response within the intestinal mucosa leads to inflammation in genetically predisposed individuals. Multifactorial evidence suggests that a defect of innate immune response to microbial agents, as well as abnormalities in adaptive immunity and epithelial barrier function are involved in IBD.1



This chapter was written by Stephen B. Hanauer, Wee-Chian Lim, and Miles Sparrow in the ­previous version of this textbook. The author wishes to thank Stacey Grabert, Pharm.D., MS, for editorial assistance in preparing this manuscript.


  1. 1.
    Torres MI, Rios A. Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J Gastroenterol. 2008;14(13):1972–80.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Summers RW, Switz DM, Sessions Jr JT, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77(4 Pt 2):847–69.PubMedGoogle Scholar
  3. 3.
    Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86(2):249–66.PubMedGoogle Scholar
  4. 4.
    Van Hees PA, Van Lier HJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn’s disease: a controlled double-blind study. Gut. 1981;22(5):404–9.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Anthonisen P, Barany F, Folkenborg O, et al. The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn’s disease. A controlled double-blind study. Scand J Gastroenterol. 1974;9(6):549–54.PubMedGoogle Scholar
  6. 6.
    Feagan BG. Aminosalicylates for active disease and in the maintenance of remission in Crohn’s disease. Eur J Surg. 1998;164(12):903–9.PubMedGoogle Scholar
  7. 7.
    Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973;289(10):491–5.PubMedGoogle Scholar
  8. 8.
    Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut. 1991;32(9):1071–5.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. II. Result. Gastroenterology. 1982;83(3):550–62.PubMedGoogle Scholar
  10. 10.
    Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn’s disease. Can J Gastroenterol. 1998;12(1):53–6.PubMedGoogle Scholar
  11. 11.
    Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn’s disease: a randomized controlled trial. Gastroenterology. 2002;123(1): 33–40.PubMedGoogle Scholar
  12. 12.
    Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol. 1999;94(3):674–8.PubMedGoogle Scholar
  13. 13.
    Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1996;91(2):328–32.PubMedGoogle Scholar
  14. 14.
    Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn’s disease. Curr Med Res Opin. 2005;21(8):1165–9.PubMedGoogle Scholar
  15. 15.
    Otley A, Steinhart AH. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2005;4:CD000296.Google Scholar
  16. 16.
    Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994;331(13):836–41.PubMedGoogle Scholar
  17. 17.
    Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn’s disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002;97(7):1748–54.PubMedGoogle Scholar
  18. 18.
    Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998;339(6):370–4.PubMedGoogle Scholar
  19. 19.
    Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn’s disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol. 1996;8(9):905–9.PubMedGoogle Scholar
  20. 20.
    Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331(13):842–5.PubMedGoogle Scholar
  21. 21.
    Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli Budesonide Study Group. Gastroenterology. 1998;115(4):835–40.PubMedGoogle Scholar
  22. 22.
    Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut. 1997;41(2):209–14.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996;110(1):45–51.PubMedGoogle Scholar
  24. 24.
    Ferguson A, Campieri M, Doe W, Persson T, Nygard G. Oral budesonide as maintenance therapy in Crohn’s disease – results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther. 1998;12(2):175–83.PubMedGoogle Scholar
  25. 25.
    Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn’s disease. A placebo controlled one year study. Gut. 1996;39(1):82–6.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(4):363–71.PubMedGoogle Scholar
  27. 27.
    Simms L, Steinhart AH. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2001;1:CD002913.Google Scholar
  28. 28.
    Faubion Jr WA, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255–60.PubMedGoogle Scholar
  29. 29.
    Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35(3):360–2.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Franchimont DP, Louis E, Croes F, Belaiche J. Clinical pattern of corticosteroid dependent Crohn’s disease. Eur J Gastroenterol Hepatol. 1998;10(10):821–5.PubMedGoogle Scholar
  31. 31.
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123(2):132–42.PubMedGoogle Scholar
  32. 32.
    Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut. 1995;37(5):674–8.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–5.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.PubMedGoogle Scholar
  35. 35.
    Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther. 2005;21(4):307–19.PubMedGoogle Scholar
  36. 36.
    Hayee BH, Harris AW. Methotrexate for Crohn’s disease: experience in a district general hospital. Eur J Gastroenterol Hepatol. 2005;17(9):893–8.PubMedGoogle Scholar
  37. 37.
    Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2005;1:CD003459.Google Scholar
  38. 38.
    Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332(5):292–7.PubMedGoogle Scholar
  39. 39.
    Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn’s disease. Aliment Pharmacol Ther. 2001;15(1):35–44.PubMedGoogle Scholar
  40. 40.
    Lemann M, Chamiot-Prieur C, Mesnard B, et al. Methotrexate for the treatment of refractory Crohn’s disease. Aliment Pharmacol Ther. 1996;10(3):309–14.PubMedGoogle Scholar
  41. 41.
    Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn’s disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000;95(7):1730–4.PubMedGoogle Scholar
  42. 42.
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000;342(22):1627–32.PubMedGoogle Scholar
  43. 43.
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35.PubMedGoogle Scholar
  44. 44.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.PubMedGoogle Scholar
  45. 45.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–405.PubMedGoogle Scholar
  46. 46.
    Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005;128(4):862–9.PubMedGoogle Scholar
  47. 47.
    Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004;63(12):1664–9.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–9.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Herfarth H, Obermeier F, Andus T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn’s disease. Am J Gastroenterol. 2002;97(10): 2688–90.PubMedGoogle Scholar
  50. 50.
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.PubMedGoogle Scholar
  52. 52.
    Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease – seven years on. Aliment Pharmacol Ther. 2006;23(4):451–63.PubMedGoogle Scholar
  53. 53.
    Schroder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn’s disease: a controlled pilot study. Eur J Gastroenterol Hepatol. 2006;18(1):11–6.PubMedGoogle Scholar
  54. 54.
    Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357(3):228–38.PubMedGoogle Scholar
  55. 55.
    Rutgeerts PJ, Mellili LE, Li J, Pollack PF. Adalimumab maintains improvement in IBDQ scores over 1 year following the initial attainment of remission in patients with moderately severely active Crohn’s disease: results of the Classic II study. Gastroenterology. 2006;130:A479.Google Scholar
  56. 56.
    Sandborn WJ, Hanauer S, Loftus Jr EV, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol. 2004;99(10):1984–9.PubMedGoogle Scholar
  57. 57.
    Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005;100(1):75–9.PubMedGoogle Scholar
  58. 58.
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33. quiz 591.PubMedGoogle Scholar
  59. 59.
    Sandborn W, Rutgeerts P, Enns RA, Hanauer SB, ­Colombel JF, Panaccione R, et al. Adalimumab rapidly induces clinical remission and response in patients with moderate to severe Crohn’s disease who had secondary failure to infliximab therapy: results of the GAIN study. Am J Gastroenterol. 2006;101(Abstract):S448.Google Scholar
  60. 60.
    Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129(3): 807–18.PubMedGoogle Scholar
  61. 61.
    Schreiber S, Khaliq-Kareemi M, Lawrence I, Hanauer SB, McColm J, Bloomfield R, et al. Certolizumab pegol, a humanized anti-TNF pegylated FAb fragment is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a phase III study (PRECiSE II). Gut. 2005;54(Abstract):A82.Google Scholar
  62. 62.
    Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease: an exploratory study. Aliment Pharmacol Ther. 2004;20(11–12):1337–46.PubMedGoogle Scholar
  63. 63.
    Sandborn W, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, McColm JA, et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26 week, placebo controlled phase II study (PRECiSE 1). Gastroenterology. 2006;130(Abstract):A107.Google Scholar
  64. 64.
    Rutgeerts P, D’Haens GR, Van Assche GA, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn’s disease – first results of the EXTEND trial. Program and abstracts from Digestive Disease Week, 30 May–4 June 2009, Chicago, IL. Abstract 751e.Google Scholar
  65. 65.
    Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58(7):940–8.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Lofberg R, Louis E, Reinisch W, et al. Adalimumab induces sustained fistula healing in both anti-TNF-Naïve and anti-TNF-experienced patients with Crohn’s disease: The Care Trial. Program and abstracts from Digestive Disease Week, 30 May–4 June 2009, Chicago, IL. Abstract S1144.Google Scholar
  67. 67.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357(3):239–50.PubMedGoogle Scholar
  68. 68.
    D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660–7.PubMedGoogle Scholar
  69. 69.
    Sandborn W, Rutgeerts P, Reinisch W, et al. SONIC: A randomized double-blind, controlled trial comparing infliximab and infliximab and azathioprine to azathioprine in patients with Crohn’s disease naive to immunomodulators and biologic therapy. Am J Gastroenterol. 2008;103:1117. Abstract 29.Google Scholar
  70. 70.
    Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Li J, et al. Early Crohn’s disease shows high levels of remission to therapy with adalimumab: sub-analysis of Charm. Gastroenterology. 2007;132(4 Suppl 2):A-147.Google Scholar
  71. 71.
    Panaccione RCJ, Enns R, Feagan B, Hanauer S, Lawrence I, Rutgeerts P, et al. Natalizumab maintains remission in patients with moderately to severely active Crohn’s disease for up to 2 years: results from an open-label extension study. Gastroenterology. 2006;130(Abstract):A111.Google Scholar
  72. 72.
    Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. N Engl J Med. 2003;348(1):24–32.PubMedGoogle Scholar
  73. 73.
    Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–25.PubMedGoogle Scholar
  74. 74.
    Targan S, Feagan B, Fedorak R, Lashner B, Panacionne R, Present D, et al. Natalizumab induces sustained response and remission in patients with active Crohn’s disease: results from the ENCORE trial. Gastroenterology. 2006;130(Abstract):A108.Google Scholar
  75. 75.
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8.PubMedGoogle Scholar
  76. 76.
    Afif W, Loftus EV Jr, Faubion W et al. Clinical utility of measuring infliximab and human anti-chimeric antibody ­concentrations in patients with inflammatory bowel ­disease. Am J Gastroenterol. 2010;105(5):1133–9.Google Scholar
  77. 77.
    Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–38.PubMedGoogle Scholar
  78. 78.
    Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2(7):542–53.PubMedGoogle Scholar
  79. 79.
    FDA Consumer Resources Page. Food and Drug Administration Web site. (2008). Accessed 12 Nov 2009.
  80. 80.
    Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology. 2007;133(1):312–39.PubMedGoogle Scholar
  81. 81.
    Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7(8):874–81.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354(9):924–33.PubMedPubMedCentralGoogle Scholar
  83. 83.
    FDA Drug Safety Page. Food and Drug Administration Web site. (2008). Accessed 15 Nov 2009.
  84. 84.
    van Dieren JM, Kuipers EJ, Samsom JN, Nieuwenhuis EE, van der Woude CJ. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis. 2006;12(4):311–27.PubMedGoogle Scholar
  85. 85.
    Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17(10):1273–81.PubMedGoogle Scholar
  86. 86.
    Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn’s disease and steroid resistance. Aliment Pharmacol Ther. 2001;15(3):371–7.PubMedGoogle Scholar
  87. 87.
    Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis. 1999;5(4):239–45.PubMedGoogle Scholar
  88. 88.
    Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology. 2003;125(2):380–8.PubMedGoogle Scholar
  89. 89.
    de Oca J, Vilar L, Castellote J, et al. Immunodulation with tacrolimus (FK506): results of a prospective, open-label, non-controlled trial in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2003;95(7):465–70. 459–64.PubMedGoogle Scholar
  90. 90.
    Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn’s disease. Gut. 2000;47(3):436–40.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Lukas M. What is the time for surgery in severe Crohn’s disease? Inflamm Bowel Dis. 2008;14:S271–2.PubMedGoogle Scholar
  92. 92.
    Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2005;(1):CD003715.Google Scholar
  93. 93.
    Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in Crohn’s disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1996;110(3):688–93.PubMedGoogle Scholar
  94. 94.
    Blum E, Katz JA. Postoperative therapy for Crohn’s disease. Inflamm Bowel Dis. 2009;15(3):463–72.PubMedGoogle Scholar
  95. 95.
    Achkar JP, Hanauer SB. Medical therapy to reduce postoperative Crohn’s disease recurrence. Am J Gastroenterol. 2000;95(5):1139–46.PubMedGoogle Scholar
  96. 96.
    Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113(5):1465–73.PubMedGoogle Scholar
  97. 97.
    Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology. 2000;118(2):264–73.PubMedGoogle Scholar
  98. 98.
    Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127(3):723–9.PubMedGoogle Scholar
  99. 99.
    Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55(1):47–53.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology. 2004;127(3):730–40.PubMedGoogle Scholar
  101. 101.
    Sorrentino D, Terrosu G, Avellini C, Beltrami CA, Bresadola V, Toso F. Prevention of postoperative recurrence of Crohn’s disease by infliximab. Eur J Gastroenterol Hepatol. 2006;18(4):457–9.PubMedGoogle Scholar
  102. 102.
    Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136(2):441–50.e1. quiz 716.PubMedGoogle Scholar
  103. 103.
    Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108(6):1617–21.PubMedGoogle Scholar
  104. 104.
    Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med. 2001;135(10):906–18.PubMedGoogle Scholar
  105. 105.
    Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn’s disease with metronidazole. ­Gastroenterology. 1980;79(2):357–65.PubMedGoogle Scholar
  106. 106.
    Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology. 1982;83(2):383–7.PubMedGoogle Scholar
  107. 107.
    Jakobovits J, Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol. 1984;79(7):533–40.PubMedGoogle Scholar
  108. 108.
    Mahadevan U, Marion JF, Present DH. Fistula response to methotrexate in Crohn’s disease: a case series. Aliment Pharmacol Ther. 2003;18(10):1003–8.PubMedGoogle Scholar
  109. 109.
    Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998;41(1):93–7.PubMedGoogle Scholar
  110. 110.
    Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95(5):1263–76.PubMedGoogle Scholar
  111. 111.
    Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol. 1996;8(6):549–53.PubMedGoogle Scholar
  112. 112.
    Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92(10):1867–71.PubMedGoogle Scholar
  113. 113.
    Lee FI, Jewell DP, Mani V, et al. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut. 1996;38(2):229–33.PubMedPubMedCentralGoogle Scholar
  114. 114.
    Nielsen OH. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1982;17(3):389–93.PubMedGoogle Scholar
  115. 115.
    Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000543.Google Scholar
  116. 116.
    Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54(7):960–5.PubMedPubMedCentralGoogle Scholar
  117. 117.
    Sands BE. Fulminant colitis. J Gastrointest Surg. 2008;12(12): 2157–9.PubMedGoogle Scholar
  118. 118.
    George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol. 1996;91(9):1711–4.PubMedGoogle Scholar
  119. 119.
    Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990;85(6):717–22.PubMedGoogle Scholar
  120. 120.
    Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50(4):485–9.PubMedPubMedCentralGoogle Scholar
  121. 121.
    Naftali T, Novis B, Pomeranz I, et al. Cyclosporine for severe ulcerative colitis. Isr Med Assoc J. 2000;2(8):588–91.PubMedGoogle Scholar
  122. 122.
    Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330(26):1841–5.PubMedGoogle Scholar
  123. 123.
    Svavoni F, Bonassi U, Bonassi F. Effectiveness of cyclosporine in the treatment of refractory ulcerative colitis. Gastroenterology. 1998;114:A1096.Google Scholar
  124. 124.
    Hogenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther. 2003;18(4):415–23.PubMedGoogle Scholar
  125. 125.
    Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55(9):1255–62.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.PubMedGoogle Scholar
  127. 127.
    Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137(4):1250–60. quiz 1520.PubMedGoogle Scholar
  128. 128.
    Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000;95(7):1749–54.PubMedGoogle Scholar
  129. 129.
    Mantzaris GJ, Hatzis A, Petraki K, Spiliadi C, Triantaphyllou G. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum. 1994;37(1):58–62.PubMedGoogle Scholar
  130. 130.
    Dignass A, Veerman H. Once versus twice daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis: the result from a multinational study. Gut. 2008;57 Suppl 1:A1.Google Scholar
  131. 131.
    Kruis W, Gorelov A, Kiudelis G. Once daily dosing of 3g mesalamine is therapeutic equivalent to a three times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterology. 2007;132:A130.Google Scholar
  132. 132.
    Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol. 1997;25(1):330–3.PubMedGoogle Scholar
  133. 133.
    Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(1):CD000478.Google Scholar
  134. 134.
    Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2003;(3):CD000543.Google Scholar
  135. 135.
    Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305(6844):20–2.PubMedPubMedCentralGoogle Scholar
  136. 136.
    Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125(2):320–7.PubMedGoogle Scholar
  137. 137.
    Mahadevan U, Loftus Jr EV, Tremaine WJ, et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis. 2002;8(5):311–6.PubMedGoogle Scholar
  138. 138.
    Reding R, Michel LA, Donckier J, de Canniere L, Jamart J. Surgery in patients on long-term steroid therapy: a tentative model for risk assessment. Br J Surg. 1990;77(10):1175–8.PubMedGoogle Scholar
  139. 139.
    Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000;23(5):429–48.PubMedGoogle Scholar
  140. 140.
    Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol. 2008;103(9):2373–81.PubMedGoogle Scholar
  141. 141.
    Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954–63.PubMedGoogle Scholar
  142. 142.
    Colombel JF, Loftus Jr EV, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99(5):878–83.PubMedGoogle Scholar
  143. 143.
    Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg. 2008;12(10):1730–6. discussion 1736–7.PubMedGoogle Scholar
  144. 144.
    Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg. 2008;12(10):1738–44.PubMedGoogle Scholar
  145. 145.
    Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204(5):956–62. discussion 962–3.PubMedGoogle Scholar
  146. 146.
    Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994;39(6):1193–6.PubMedGoogle Scholar
  147. 147.
    Maser EA, Present DH. Pouch-ouch. Curr Opin Gastroenterol. 2008;24(1):70–4.PubMedGoogle Scholar
  148. 148.
    Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305–9.PubMedGoogle Scholar
  149. 149.
    Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999;13(6):713–8.PubMedGoogle Scholar
  150. 150.
    Isaacs KL, Sandler RS, Abreu M, et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007;13(10):1250–5.PubMedGoogle Scholar
  151. 151.
    Baidoo L, Kundu R, Su C. Rifaximin is an effective antibiotic for the treatment of pouchitis. Gastroenterology. 2005;128:A797.Google Scholar
  152. 152.
    Gionchetti P, Rizzello F, Poggioli G, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther. 2007;25(10):1231–6.PubMedGoogle Scholar
  153. 153.
    Gionchetti P, Morselli C, Rizzello F, et al. Infliximab in the treatment of refractory pouchitis. Gastroenterology. 2005; 128:A578.Google Scholar
  154. 154.
    Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124(5):1202–9.PubMedGoogle Scholar
  155. 155.
    Colombel JF, Ricart E, Loftus Jr EV, et al. Management of Crohn’s disease of the ileoanal pouch with infliximab. Am J Gastroenterol. 2003;98(10):2239–44.PubMedGoogle Scholar
  156. 156.
    Shen B, Remzi FH, Shen L. Efficacy and safety of adalimumab in the treatment of Crohn’s disease of the ileal pouch. The annual meeting of the American College of Gastroenterology, Orlando, FL; 2008. Abstract:620.Google Scholar

Copyright information

© ASCRS (American Society of Colon and Rectal Surgeons) 2011

Authors and Affiliations

  • Bruce E. Sands
    • 1
    • 2
  1. 1.MGH Crohn’s and Colitis CenterHarvard School of MedicineBostonUSA
  2. 2.Massachusetts General HospitalBostonUSA

Personalised recommendations